President Trump Will Announce New Medicaid Drug Pricing
The policy change aims to lower prescription costs for patients across all 50 states.
Updated on Sept. 18, 2026 in Economic Policy
Live Poll
Should the federal government regulate prescription drug prices to reduce costs for patients?
President Trump will announce new Medicaid drug pricing policies during an event in the Oval Office on September 19, 2026. This administrative move is designed to lower prescription drug costs by granting Medicaid access to most favored nation pricing.
Why it matters
The administration is targeting drug affordability as a key priority ahead of upcoming midterm elections. By adjusting how Medicaid programs purchase pharmaceuticals, the policy seeks to curb spending across the national healthcare system.
The new policy mandates that Medicaid programs in all 50 states receive most favored nation pricing for certain medications. The official announcement is scheduled to take place at 2:30 p.m. EDT.
The players
President Donald Trump
He is the current President of the United States who is leading the push to reform drug purchasing agreements.
The details
President Trump will deliver remarks alongside various governors to formalize the shift in pharmaceutical procurement. The initiative specifically targets high prescription drug costs to provide relief to the Medicaid system.
Timeline
September 18, 2026: The initial reports regarding the policy change were published.
September 19, 2026, at 2:30 p.m. EDT: The President will officially announce the pricing changes.
Macro View
This policy initiative mirrors previous attempts to leverage federal purchasing power to influence market rates for pharmaceuticals. By applying the Most Favored Nation drug pricing model to Medicaid, the administration is following a long-term trend of seeking to lower healthcare costs through government intervention.
The change will directly impact how state-level Medicaid programs pay for specific prescription drugs. Ultimately, the policy aims to curb government spending on pharmaceuticals, which may lead to broader shifts in how medications are priced for the public.
The takeaway
The move represents a significant effort to lower prescription drug spending by shifting the procurement model for state programs. Voters should track how these changes influence drug availability and program costs in their respective states.
Further reading
For additional context on government efforts to control healthcare costs, visit the Economic Policy section.
Live Poll
Should the federal government regulate prescription drug prices to reduce costs for patients?
